In today’s session Insys Therapeutics Inc (INSY) registered an unusually high (552) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious INSY increase. With 552 contracts traded and 3254 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: INSY161118C00012000 closed last at: $1.95 or 30% up. About 143,336 shares traded hands. Insys Therapeutics Inc (NASDAQ:INSY) has declined 32.02% since March 2, 2016 and is downtrending. It has underperformed by 40.28% the S&P500.
Analysts await Insys Therapeutics Inc (NASDAQ:INSY) to report earnings on November, 3. INSY’s profit will be $4.17M for 53.13 P/E if the $0.06 EPS becomes a reality. After $0.06 actual EPS reported by Insys Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Insys Therapeutics Inc (NASDAQ:INSY) Ratings Coverage
Out of 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $30 is the highest target while $17 is the lowest. The $25 average target is 96.08% above today’s ($12.75) stock price. Insys Therapeutics has been the topic of 8 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Janney Capital given on Thursday, April 14. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. As per Tuesday, April 12, the company rating was maintained by Jefferies. Oppenheimer maintained Insys Therapeutics Inc (NASDAQ:INSY) on Tuesday, August 4 with “Hold” rating. The rating was downgraded by Zacks to “Buy” on Friday, August 14. The firm has “Buy” rating by Jefferies given on Thursday, August 4. Jefferies maintained the shares of INSY in a report on Wednesday, February 24 with “Buy” rating. RBC Capital Markets maintained Insys Therapeutics Inc (NASDAQ:INSY) on Thursday, September 22 with “Outperform” rating.
According to Zacks Investment Research, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.”
Insitutional Activity: The institutional sentiment decreased to 0.7 in 2016 Q2. Its down 0.36, from 1.06 in 2016Q1. The ratio is negative, as 22 funds sold all Insys Therapeutics Inc shares owned while 42 reduced positions. 13 funds bought stakes while 32 increased positions. They now own 31.30 million shares or 9.76% less from 34.69 million shares in 2016Q1.
Van Eck Assocs holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 234 shares. Nationwide Fund Advsr holds 15,183 shares or 0% of its portfolio. Vanguard Grp Inc last reported 2.38M shares in the company. Clinton Group Inc Incorporated Inc has invested 0.01% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Alliancebernstein Limited Partnership holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 61,120 shares. Moreover, Tower Rech Capital Limited Liability Com (Trc) has 0% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 47 shares. Tiaa Cref Investment Mngmt Ltd Co, a New York-based fund reported 71,454 shares. Bank Of America Corporation De holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 13,125 shares. The California-based Cypress Funds Limited Liability Company has invested 0.41% in Insys Therapeutics Inc (NASDAQ:INSY). Moreover, New York State Common Retirement Fund has 0% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 22,700 shares. Tci Wealth reported 3,545 shares or 0.03% of all its holdings. Blackrock Fund owns 1.48 million shares or 0% of their US portfolio. Weiss Multi accumulated 0.02% or 21,510 shares. 12 West Mngmt L P has 1.3% invested in the company for 623,791 shares. State Board Of Administration Of Florida Retirement Systems reported 17,901 shares or 0% of all its holdings.
Insider Transactions: Since May 11, 2016, the stock had 2 insider purchases, and 4 selling transactions for $170,592 net activity. $110,752 worth of Insys Therapeutics Inc (NASDAQ:INSY) was sold by BRENNAN DANIEL on Tuesday, August 9. 16,000 shares were sold by STANLEY THEODORE H, worth $260,320. 15,000 shares were sold by FOURTEAU PATRICK, worth $276,900. Shares for $641,827 were bought by JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The company has a market cap of $886.81 million. The Firm develops and commercializes supportive care products. It has a 19.36 P/E ratio. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
INSY Company Profile
Insys Therapeutics, Inc., incorporated on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Firm develops and commercializes supportive care products. Subsys is the Company’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Firm markets Subsys through its field sales force focused on supportive care physicians in the United States.
More news for Insys Therapeutics Inc (NASDAQ:INSY) were recently published by: Globenewswire.com, which released: “Insys Therapeutics Announces CEO Succession Plan” on September 21, 2016. Businessinsider.com‘s article titled: “A pharmaceutical company is fighting marijuana legalization because it would …” and published on September 13, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.